The beta-gal interferon assay: a new, precise and sensitive method |
| |
Authors: | U Hammerling E Bongcam-Rudloff N Setterblad R Kroon AK Rehnstr?m E Viitanen G Andersson L Sj?din |
| |
Affiliation: | Division of Biotechnology, Medical Products Agency, Uppsala, Sweden. ulf.hammerling@eurona.se |
| |
Abstract: | Cells of a human glioblastoma line were stably transfected with a glial fibrillary acidic protein (GFAP) promoter sequence/lacZ reporter gene. Following this modification, they produced Escherichia coli beta-galactosidase constitutively in amounts that could be measured through their conversion of an added fluorophore into a product readily estimated by fluorimetry. Human interferons (IFN) selectively and in a dose-dependent manner reduce the formation of beta-galactosidase in this system. We have used it as the basis for a novel assay that is sensitive (4-40 pg/ml), precise, completed in 30 h, and applicable to both type I and type II human IFNs. Statistical analysis showed interassay relative standard deviations ranging from 5% to 11%, and most individual assays revealed potencies with limits of error within 85%-115%. Neither partially trypsin-digested IFN nor the other cytokines and mitogens we tested reacted in this system, except for tumor necrosis factor-alpha (TNF-alpha). The high selectivity was further shown by the loss of response to IFN in the presence of the appropriate specific anti-IFN or anti-IFN-gamma receptor antibodies. |
| |
Keywords: | |
本文献已被 PubMed 等数据库收录! |
|